Author profile
Johns Hopkins University
Advances in ‘first-principles’ models of radiation response allow, in principle, for accurate mechanism-aware prediction of how biological effectiveness and effective linear quadratic (LQ) parameters change across various experimental and clinical conditions....
Physiologically based pharmacokinetic (PBPK) models used in radiopharmaceutical therapy (RPT) and theranostic digital twins are rapidly increasing in size and mechanistic detail, often containing tens to hundreds of parameters. While such models fit imaging a...
Quantitative image-based dosimetry for radiopharmaceutical therapy (RPT) increasingly relies on large, multi-organ mechanistic models of physiologically based pharmacokinetics (PBPK). While PBPK models often fit clinical data well, the extent to which their i...
Radiopharmaceutical therapies (RPTs) effectively treat metastatic castration-resistant prostate cancer, yet injected radioactivities remain empirically prescribed. Although physiologically-based pharmacokinetic (PBPK) and pharmacodynamic (PD) models can separ...
In prostate-specific membrane antigen (PSMA)-targeted radiopharmaceutical therapy for metastatic castration-resistant prostate cancer, salivary glands often receive unintended high absorbed doses and are considered dose-limiting organs. For radiopharmaceutica...
Computational nuclear oncology (CNO) methods are advancing rapidly but often developed in isolated tools and workflows that are difficult to reproduce, compare, and share. This fragmentation limits virtual studies and slows translation of physiologically base...